explore -WSS

explore

author：leisure time 2025-09-02 17:35:48 - browse：4349

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Illumina board agrees to spin off Grail, as divestment plans proceed

hotspot

WSS

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Unmasking the 'centricity' illusion in clinical trials

U.S. death rates show how politics are affecting public health

Eli Lilly’s Zepbound improved liver scarring in mid

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Wikipedia

explore

focus

Supreme Court strikes down use of affirmative action

The most pressing bird flu mysteries scientists want answered

State Dept. review finds Biden bears some blame for Afghanistan failures

Why some fertility treatments produce more boy babies

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How CO2 helps viruses stay alive longer in the air

Medicare details structure of new drug price negotiation program

FDA approves Moderna’s RSV vaccine, its second licensed product

Bright Health sells Medicare Advantage business to Molina

Anthony Fauci pushes back on GOP claims during Covid hearing

knowledge

Protect nursing home residents from future pandemics

Illumina board agrees to spin off Grail, as divestment plans proceed

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

A new initiative will help leaders fight the next pandemic

Why we need mandatory labeling of GMO products

Take antibiotics after sex, CDC recommends for certain risk groups

Wikipedia

hotspot

hotspot

explore